Is This Chinese Pharmaceutical Stock Worth the Risk?
BeiGene (NASDAQ: BGNE), is a Chinese biopharmaceutical company with offices in Cambridge, Massachusetts; Basel, Switzerland; and Beijing. It focuses on unique therapies to treat cancer, specializing in B-cell malignancies and solid tumors in lung and gastrointestinal cancers. Amid delisting concerns, a lot of Chinese stocks have fallen this year.